- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
Patent holdings for IPC class C07D 403/12
Total number of patents in this class: 9821
10-year publication summary
|
556
|
597
|
550
|
623
|
597
|
562
|
689
|
580
|
480
|
82
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4793 |
207 |
| Boehringer Ingelheim International GmbH | 4576 |
157 |
| F. Hoffmann-La Roche AG | 7882 |
137 |
| Novartis AG | 10463 |
126 |
| Janssen Pharmaceutica N.V. | 3298 |
105 |
| Vertex Pharmaceuticals Incorporated | 1611 |
100 |
| BASF SE | 21131 |
98 |
| Hoffmann-La Roche Inc. | 3640 |
96 |
| AstraZeneca AB | 2824 |
89 |
| Pfizer Inc. | 3377 |
88 |
| Genentech, Inc. | 4058 |
86 |
| Merck Sharp & Dohme LLC | 3719 |
86 |
| Merck Patent GmbH | 5741 |
84 |
| Takeda Pharmaceutical Company Limited | 2722 |
74 |
| Gilead Sciences, Inc. | 2157 |
71 |
| Bayer AG | 3417 |
61 |
| Amgen Inc. | 4318 |
58 |
| Array BioPharma Inc. | 468 |
56 |
| Dana-Farber Cancer Institute, Inc. | 2641 |
55 |
| The Regents of the University of California | 20447 |
54 |
| Other owners | 7933 |